Detalhe da pesquisa
1.
Defining the molecular evolution of extrauterine high grade serous carcinoma.
Gynecol Oncol
; 155(2): 305-317, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31493898
2.
Prior knowledge transfer across transcriptional data sets and technologies using compositional statistics yields new mislabelled ovarian cell line.
Nucleic Acids Res
; 44(17): e137, 2016 09 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-27353327
3.
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.
Nature
; 434(7035): 917-21, 2005 Apr 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-15829967
4.
ATM Kinase Inhibition Preferentially Sensitises PTEN-Deficient Prostate Tumour Cells to Ionising Radiation.
Cancers (Basel)
; 13(1)2020 Dec 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-33396656
5.
miR-191 promotes radiation resistance of prostate cancer through interaction with RXRA.
Cancer Lett
; 473: 107-117, 2020 03 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-31874245
6.
DNA Repair Deficiency in Breast Cancer: Opportunities for Immunotherapy.
J Oncol
; 2019: 4325105, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31320901
7.
A Novel Role for Cathepsin S as a Potential Biomarker in Triple Negative Breast Cancer.
J Oncol
; 2019: 3980273, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31346333
8.
Activation of MAPK signalling results in resistance to saracatinib (AZD0530) in ovarian cancer.
Oncotarget
; 9(4): 4722-4736, 2018 Jan 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29435137
9.
FES-related tyrosine kinase activates the insulin-like growth factor-1 receptor at sites of cell adhesion.
Oncogene
; 37(23): 3131-3150, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29540831
10.
X-chromosome inactivation: X marks the spot for BRCA1.
Curr Biol
; 13(2): R63-4, 2003 Jan 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-12546807
11.
Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer.
J Natl Cancer Inst
; 109(1)2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27707838
12.
BRCA1 interacts with and is required for paclitaxel-induced activation of mitogen-activated protein kinase kinase kinase 3.
Cancer Res
; 64(12): 4148-54, 2004 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-15205325
13.
When the guardian becomes the enemy: Targeting ATM in PTEN-deficient cancers.
Mol Cell Oncol
; 3(1): e1053595, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-27308567
14.
IGF-1R inhibition sensitizes breast cancer cells to ATM-related kinase (ATR) inhibitor and cisplatin.
Oncotarget
; 7(35): 56826-56841, 2016 08 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-27472395
15.
BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of Poly (ADP-Ribose) polymerase: an issue of potency.
Cancer Biol Ther
; 4(9): 934-6, 2005 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-16251802
16.
Mechanistic Rationale to Target PTEN-Deficient Tumor Cells with Inhibitors of the DNA Damage Response Kinase ATM.
Cancer Res
; 75(11): 2159-65, 2015 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25870146
17.
Potentiation of inflammatory CXCL8 signalling sustains cell survival in PTEN-deficient prostate carcinoma.
Eur Urol
; 64(2): 177-88, 2013 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-22939387
18.
The role of PTEN as a cancer biomarker.
Oncoscience
; 3(2): 54-5, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27014722
19.
DNA polymerases as potential therapeutic targets for cancers deficient in the DNA mismatch repair proteins MSH2 or MLH1.
Cancer Cell
; 17(3): 235-48, 2010 Mar 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-20227038
20.
Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition.
Cancer Res
; 66(16): 8109-15, 2006 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-16912188